Reminyl
Developed to address cognitive decline in patients to support memory function.
Strengths: 4 · 8mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Acumerck
- Therapeutic class
Acetylcholinesterase inhibitor
- Pharmacological class
Acetylcholinesterase inhibitor
- Contraindications
severe hepatic impairment; severe renal impairment
- Minor side effects
nausea; vomiting; dizziness
- Moderate side effects
diarrhoea; abdominal pain; fatigue
- Dosage forms
Tablet
- Administration route
Oral use
- Patient summary
Developed to address cognitive decline in patients to support memory function.
- Prescription status
POM
- Manufacturer
Janssen
- Onset Time
1 hour
- Duration
12 hours
- Storage instructions
Store in a cool, dry place.
- Drug interactions
anticholinergics; beta-blockers
- Age restrictions
Not recommended for children.
- Pregnancy and breastfeeding
Pregnancy: Use only if clearly necessary. Breastfeeding: Not recommended.
Precautions and warnings
monitor for weight loss; use with care in patients with cardiac conduction disturbances; maintain adequate hydration during treatment
Serious side effects
bradycardia — requires immediate medical attention; syncope — requires immediate medical attention; seizures — requires immediate medical attention
Mechanism of action
It functions as a centrally acting acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, increasing acetylcholine levels available for neuronal signalling.
Reminyl
Developed to address cognitive decline in patients to support memory function.
Editorial Notes
- Active ingredient(s): Galantamine
- Listed indication(s): Alzheimer’s Disease
Usually available as
- 60 tablets - 4 mg653-4-mg-6213
- 30 tablets - 8 mg653-8-mg-4064